

Faculty Disclosures

Educational Review Systems (ERS) requires CME faculty and others in a position to influence the content of the CME activity to disclose any real or apparent conflict of interest related to presentation and discussion content. For this CME activity, resolution of any such conflict of interest has been accomplished through review of the program content by ERS. For this activity, the following relationships have been disclosed:

Alan F. List, MD

Research Sponsorship/Funding: Celgene Corporation

Speakers Bureau/Honorariums: Celgene Corporation

Advisory Board: Celgene Corporation

Consultant: S*BIO Pte Ltd

Principal Investigator: Novartis Pharmaceuticals

Additional Disclosures:

John Horton, MB, ChB, served as an independent reviewer and reports no commercial relationship germane to this CME activity.

John M. York, PharmD, Akita Biomedical Consulting, served as the activity planner and reports no commercial relationship germane to this CME activity.

Evelyn R. Hermes-DeSantis, PharmD, BCPS, served as the medical writer and reports no commercial relationship germane to this CME activity.

Discussion of Off-Label/Investigational Uses of Commercial Products

This activity contains information about experimental and other uses of drugs or devices that are not currently approved by the FDA and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

Funding for this monograph has been provided through an unrestricted educational grant from Novartis Oncology. Sponsorship of this monograph does not imply the sponsor's agreement with the views expressed herein. Every effort has been made to ensure that drug usage and other information are presented accurately; however, the ultimate responsibility rests with the prescribing physician. ERS, Akita Biomedical Consulting and its editorial staff, Cancer Control Journal, and Alan F. List, MD, shall not be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound at present under clinical investigation.

This activity has been supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation.